Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O3IT
|
||||
| Former ID |
DCL000151
|
||||
| Drug Name |
L-NMMA
|
||||
| Synonyms |
Targinina; Targinine; Targininum; Tilarginina; Tilargininum; Acetic acid; Tilarginine Acetate; Tilarginine acetate [USAN]; ANO 1020; M 7033; M1365; L-Monomethylarginine; N-Monomethyl-L-arginine; NG-Methyl-L-arginine acetate salt; NG-Monomethyl-L-arginine acetate; NG-Monomethyl-L-arginine acetate salt; NG-monomethyl-L-argine; Ngamma-Monomethyl-L-arginine; Nomega-Me-L-Arg; Nomega-Methyl-L-arginine Acetate; Nomega-Methyl-L-arginine acetate salt; Nomega-Monomethyl-L-arginine Acetate; N(G)-Methyl-L-arginine acetate; N-omega-monomethyl-L-arginine; N5-(Methylamidino)-L-ornithine acetate salt; NG-Me-L-Arg, AcOH; NG-Monomethyl-L-arginine, Monoacetate Salt; L-Ornithine, N5-[imino(methylamino)methyl]-[CAS]; N(5)-(methylamidino)-L-ornithine; N(5)-(metilamidino)-L-ornitina; N(5)-[imino(methylamino)methyl]-L-ornithine; N5-(Imino(methylamino)methyl)-L-ornithine monoacetate; N5-(N-methylcarbamimidoyl)-L-ornithine; N(5)-(N-methylcarbamimidoyl)-L-ornithine; Acide (2S)-2-amino-5-(3-methylguanidino)pentanoique; L-Ornithine, N5-(imino(methylamino)methyl)-, monoacetate; N5-(n-methylcarbamimidoyl)-l-ornithineacetate(1:1); (2S)-2-amino-5-(N'-methylcarbamimidamido)pentanoic acid; (2S)-2-amino-5-[(N'-methylcarbamimidoyl)amino]pentanoic acid; (2S)-2-amino-5-{[imino(methylamino)methyl]amino}pentanoic acid; 546C88
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Angina pectoris [ICD9: 413; ICD10:I20] | Discontinued in Phase 2 | [545605] | ||
| Company |
Cayman
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C7H16N4O2
|
||||
| Canonical SMILES |
CN=C(N)NCCCC(C(=O)O)N
|
||||
| InChI |
1S/C7H16N4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11)/t5-/m0/s1
|
||||
| InChIKey |
NTNWOCRCBQPEKQ-YFKPBYRVSA-N
|
||||
| CAS Number |
CAS 64-19-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
6617, 11110637, 11111490, 11113694, 11372893, 11372973, 11491752, 11491772, 14772879, 14772880, 15322211, 26683844, 29310898, 47721030, 47736717, 48110685, 49693484, 49737750, 50104567, 50104568, 50122590, 56310852, 57344287, 79790729, 90340995, 103143755, 103562638, 104054947, 104378393, 117541473, 124749967, 127330170, 127330171, 128752680, 134338831, 134992596, 137127260, 137137500, 139137890, 140341561, 163340035, 163340037, 175453372, 176226516, 198967182, 215780475, 223535804, 226654376, 250136969, 252350351
|
||||
| ChEBI ID |
ChEBI:28229
|
||||
| SuperDrug ATC ID |
G01AD02; S02AA10
|
||||
| Target and Pathway | |||||
| Target(s) | Nitric-oxide synthase, endothelial | Target Info | Inhibitor | [537513], [537560], [537561] | |
| BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
| NetPath Pathway | Wnt Signaling Pathway | ||||
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Thromboxane A2 receptor signaling | |||||
| SHP2 signaling | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| PAR1-mediated thrombin signaling events | |||||
| References | |||||
| Ref 537513 | Post-resuscitation NOS inhibition does not improve hemodynamic recovery of hypoxic newborn pigs. Intensive Care Med. 2009 Jun 24. | ||||
| Ref 537560 | Gonadal hormones decrease temporomandibular joint kappa-mediated antinociception through a down-regulation in the expression of kappa opioid receptors in the trigeminal ganglia. Eur J Pharmacol. 2009Jun 28. | ||||
| Ref 537561 | Gender is related to alterations of renal endothelial function in type 2 diabetes. Nephrol Dial Transplant. 2009 Jun 30. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.